The study of VEGF activation of VEGFR2 has led to the development of FDA approved therapeutics such as the anti-VEGF molecules (bevacizumab and aflibercept) and tyrosine kinase inhibitors (sorafenib and sunitinib) for the treatment of certain cancers and wet AMD [33,34]. The gene discussed is VEGFA; the disease is wet macular degeneration.